The Food and Drug Administration (FDA) has approved 2 additional vial sizes of Niktimvo ™ (axatilimab-csfr), 9mg/0.18mL and 22mg/0.44mL, in addition to the 50mg/mL size.

INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels.

US FDA approves Incyte and Syndax’s Niktimvo 9 mg & 22 mg vial sizes to treat chronic graft-versus-host disease: Wilmington, Delaware Friday, January 17, 2025, 13:30 Hrs [IST] I ...

Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic ...

Axatilimab has gained FDA approval in 9 mg and 22 mg vials, expanding treatment options for patients with chronic GVHD after ...

Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that the U.S. Food and Drug Administration has approved Niktimvo ...

U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drive ...

A YOUNG mum battling a rare form of cancer passed away surrounded by loved ones after suffering complications from treatment.

Incyte told JP Morgan attendees of plans for four launches in 2025, beginning with its FDA-approved Niktimvo for chronic GvHD ...

Choi Hyung-jin wins Im Seong-ki Researcher Award for obesity treatment breakthroughs Choi Hyung-jins groundbreaking ...

Cutaneous chronic graft-versus-host disease reduces quality of life through skin symptoms and broader impacts, guiding ...